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Abstract The world population continues to grow rapidly
while resources for sustainable living dwindle and man-
made ecological problems increase proportionally to the
overpopulation. Family planning is required to reduce popu-
lation growth in developing countries and to stabilize popu-
lations in developed countries. Contraception makes abor-
tion superfluous and provides the key to family planning.
Women increasingly demand that men share the burden
and risks of contraception and – as opinion polls show –
men would be willing to use contraceptives if they were
available. Research has established the principle of hor-
monal male contraception based on suppression of gonado-
tropins and spermatogenesis. All hormonal male contracep-
tives use testosterone, but in East Asian men, testosterone
alone can suppress spermatogenesis to a level compatible
with contraceptive protection. In Caucasians additional
agents are required of which progestins are favoured.
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Résumé La croissance de la population mondiale se poursuit
rapidement alors que les ressources pour un développement
durable s’amenuisent et que les problèmes écologiques issus
de l’activité humaine augmentent proportionnellement à la
surpopulation. Une planification familiale est nécessaire
pour réduire la croissance de la population dans les pays en
développement et pour stabiliser celle des pays développés.
La contraception rend l’avortement superflu et fournit les
clés d’une planification familiale. Les femmes demandent
de plus en plus que les hommes partagent le poids et les
risques de la contraception, et — comme le montrent les
enquêtes d’opinion — les hommes seraient prêts à utiliser
des contraceptifs s’ils étaient disponibles. La recherche a
établi le principe d’une contraception masculine hormonale
basée sur la suppression des gonadotrophines et de la sper-
matogenèse. Toute contraception masculine hormonale uti-
lise la testostérone, mais la testostérone seule ne peut réduire
la spermatogenèse à un niveau compatible avec une protec-
tion contraceptive que chez les hommes d’Extrême-Orient
(Asie de l’Est). Chez les Caucasiens, des substances addi-
tionnelles sont nécessaires pour atteindre ce niveau, parmi
lesquelles les progestatifs sont privilégiés.
Mots clés Population mondiale · Planification
familiale · Contraception masculine ·
Suppression de la spermatogenèse ·
Formes de testostérone · Androgènes de synthèse
Introduction
Men have more and more expectation and the will to share
the responsibility of family planning by using contraceptive
methods. Considering the disadvantages of traditional male
contraceptive methods (i.e. periodic abstinence, coitus inter-
ruptus, condom and vasectomy), the prerequisite for an ideal
pharmacologic male contraceptive should [1]:
• be applied independently of the sexual act;
• be acceptable for both partners;
• not interfere with libido, potency, or sexual activity;
• have neither short- nor long-term toxic side effects;
• have no impact on eventual offspring;
• be rapidly effective and fully reversible;
• be as effective and as comparable to the female methods.
Of all the different experimental approaches and pharma-
cological methods tested so far for male contraception,
hormonal methods come closest to fulfilling the criteria set
out. The endocrine feedback mechanism operating between
hypothalamus, pituitary and testes is the basis on which
hormonal approaches to male contraception rest. Its goal is
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to suppress spermatogenesis and to reduce sperm concentra-
tion, if possible, to azoospermia or at least to a sperm
concentration low enough to provide contraceptive protection
as effective as oral contraceptives in women (i.e. < 1 million
sperm per ml of ejaculate).
Sperm production and secretion of testicular testosterone
are so closely interwoven that it has remained impossible to
interrupt spermatogenesis by hormonal means without inhi-
biting androgen production. Inhibition of FSH alone, e.g., by
antibodies, leads to reduction of sperm concentration but not
to azoospermia, as monkey studies have shown [2]. Suppres-
sion of both follicle-stimulating hormone (FSH) and lutei-
nizing hormone (LH) would indeed lead to azoospermia,
but would also induce symptoms of androgen deficiency
which affects libido, potency, male role behaviour and gen-
eral metabolic processes (erythropoesis, protein, mineral and
bone metabolism). For this reason inhibition of gonadotro-
pins will always necessitate androgen administration.
Thus, the principle of hormonal male contraception is
based on [1]:
• suppression of LH and FSH;
• depletion of intratesticular testosterone and atrophy of
spermatogenesis;
• substitution of peripheral testosterone to maintain
androgenicity.
Testosterone itself is a first choice as it simultaneously
suppresses the gonadotropins and maintains androgenicity
and indeed, testosterone alone was the first hormone tested
for male contraception and remains part of any steroid
combination to date. In this article, the trials that used testo-
sterone alone for male contraception are summarized.
Natural testosterone
Testosterone enanthate
Soon after testosterone was synthesized and became avail-
able for clinical use in the late 1930s, its spermatogenesis-
suppressing effect was recognized, but not until the 1970s
did investigations start to exploit this phenomenon for male
contraception. As in most hormonal male contraceptive stu-
dies to date, in the early studies sperm concentrations and
counts were used as surrogate parameters for efficacy [3].
The first efficacy study of testosterone-based hormonal
male contraception was sponsored by the WHO and
included 10 centres on four continents [4]. Healthy fertile
participants were given 200 mg of the longer-acting testo-
sterone enanthate weekly by intramuscular injection. One
hundred fifty-seven men (70%) reached azoospermia after
6 months of treatment and entered the efficacy phase for a
further year, during which no other contraceptive was used
by the couple. Only one pregnancy was reported in this first
proof-of-principle study. Although the efficacy of this study
was very high, it cannot be used to determine the overall
efficacy of testosterone alone as a contraceptive because
only men who became azoospermic could enter the efficacy
phase while the others were excluded.
In order to clarify the question whether men developing
oligozoospermia can be considered infertile, a second world-
wide multicentre efficacy study involving 357 couples
followed [5]. In this study azoospermia again proved to be
a most effective prerequisite for contraception. If sperm con-
centration, however, failed to drop below 3 million/mL of
ejaculate, resulting pregnancy rates were higher than when
using condoms. When sperm concentrations decreased
below 3 million/mL, which was the case in 98% of the par-
ticipants, then protection was not as effective as for azoos-
permic men, but was better than that offered by condoms.
From these two WHO trials it became clear that East
Asian men responded with a higher rate of azoospermia
than Caucasian men. Although this phenomenon could
not be fully explained to date it formed the basis for very
effective trials in Chinese couples using testosterone unde-
canoate alone as described below.
Even if these WHO studies represented a breakthrough
by confirming the principle of action, they did not offer a
practicable method. For a method requiring weekly intra
muscular injections is not acceptable for broad use.
Moreover, several months, often up to one year, are required
before sperm production reaches significant suppression.
For this reason, current research is concentrating on the
development of long-acting testosterone preparations and
on methods to hasten the onset of effectiveness.
Testosterone buciclate
As long-acting testosterone preparations appeared more
promising in terms of practicability and acceptability, WHO
and the NIH initiated a synthesis program for such prepara-
tions [6] through which the long-acting testosterone ester tes-
tosterone buciclate was identified. This molecule showed a
half-life of 29.5 days when tested in hypogonadal men,
much longer than the 4.5 days of testosterone enanthate [7].
Suppression of spermatogenesis was comparable to that of
weekly testosterone enanthate injections, reaching azoosper-
mia in three out of eight volunteers after a single injection of
1200 mg of testosterone buciclate [8]. Despite its promising
pharmacokinetic profile, no industrial partner could be found
to undertake development of this preparation.
Testosterone pellets
Pellets consisting of pure testosterone are used for substi-
tution in hypogonadism in some countries. In male
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contraceptive studies, the sperm-suppressing effect was
comparable to weekly testosterone enanthate injections [9].
The disadvantage of minor surgery required for insertion
under the abdominal skin is compensated by their low
price. Spontaneous extrusion may be a disadvantage.
Testosterone undecanoate
Oral testosterone undecanoate
Initially, testosterone undecanoate was studied as an oral
preparation in volunteers of Caucasian origin [10]. Subjects
were given a daily dose of 240 mg over a period of 12 weeks,
but only one out of seven volunteers reduced sperm output
sufficiently for contraception. This low effectiveness is prob-
ably due to the short half-life of testosterone undecanoate
when given orally. Even if administered four times a day,
the peaks are not sufficient to suppress gonadotropins con-
sistently and thereby to achieve azoospermia.
Intramuscular testosterone undecanoate (TU)
• TU in tea seed oil
While testosterone undecanoate had been developed as an
oral preparation in Europe, it was turned into an injection
in China, using tea seed oil as a vehicle and is used as such
in China for hypogonadism and in trials for male contracep-
tion. Back in Europe, the half-life of this Chinese preparation
could be extended even further when dissolved in castor
oil and is now available for clinical use in 1000 mg depot
injections [11].
In the clinical trials in China, testosterone undecanoate
alone administered every 4 weeks resulted in azoospermia
in all Chinese men who received a dose of 1000 mg and in
azoospermia or severe oligozoospermia in 95% of Chinese
men who received a dose of 500 mg during a 4–6 month
suppression phase [12]. In the ensuing Phase III study
involving 305 couples, an efficacy phase followed the sup-
pression phase and no pregnancies were initiated by men
exhibiting azoospermia or severe oligozoospermia [13].
However, reappearance of sperm occurred in six men during
the efficacy phase; one pregnancy was attributed to “sperm
rebound”. Side effects observed in subjects were all typical
of elevated testosterone serum levels.
The largest efficacy study to date was also performed in
China, based on a loading dose of 1000 mg followed by
monthly injections of 500 mg testosterone undecanoate.
When sperm counts had fallen below 1 million sperm/mL,
898 men entered the efficacy phase during which only
9 pregnancies were recorded. This represents a pregnancy
rate of 1.1/100 person-years [14]. Thus, in China, testo-
sterone undecanoate provides better protection against preg-
nancy than condom use. Although injection intervals of four
weeks appeared to be an achievement over the weekly injec-
tions of testosterone enanthate, the participants in a Chinese
study considered the frequency of injections the most incon-
venient part of this regimen [15]. If testosterone undecanoate
in castor oil were to be used in China, this complaint could
certainly be overcome.
• TU in castor oil
In a first contraceptive trial of testosterone undecanoate in
castor oil 1000 mg were injected into 14 Caucasian volun-
teers at 6-week intervals. Eight of 14 men achieved azoo-
spermia [16]. Although this rate of azoospermia is not dif-
ferent from that achieved with testosterone enanthate alone,
the longer injection interval represents a significant advan-
tage. A later pharmacokinetic study concluded that 8-week
intervals of 1000 mg injections would be sufficient for con-
traceptive purposes [17].
Considering that 10 to 14-week intervals between 1000
mg testosterone undecanoate injections are required for sub-
stitution of hypogonadal men, about 1/3 more testosterone is
required for contraception in normal volunteers.
• TU in men with subnormal semen values
Clinical studies to date have only included volunteers with
“normal” semen values considered by WHO standards. As a
male contraceptive should be available to all interested men
regardless of their semen parameters, how volunteers with
subnormal semen parameters respond to hormonal male con-
traception has recently been investigated [18]. During a 34-
week treatment phase, the volunteers received injections of
1000 mg testosterone undecanoate in weeks 0, 6, 14 and 24.
This was followed by a 24-week recovery and follow-up
period. As it was not known whether men with subnormal
semen parameters would recover to starting levels, cryopres-
ervation of semen was offered to all subnormal volunteers.
Twenty-three men with normal semen parameters and
18 with sperm counts below 20 million completed the trial.
The normal volunteers showed the expected response with
17 suppressing sperm counts below 1 million/ejaculate (13
showing azoospermia) and 6 not-suppressing below 1 mil-
lion sperm/ejaculate. By the end of the recovery period all
sperm counts had returned to the range of starting values.
The subnormal group showed a similar pattern with 13/18
(=72%) men suppressing below 1 million/ejaculate (8/18 =
44% showing azoospermia) and the remaining 5/18 (=28%)
not-suppressing sperm counts below 1 million/ejaculate. All
sperm counts returned to the starting range. This demon-
strated that regarding suppressibility and reversibility, volun-
teers with normal and subnormal sperm counts display the
same pattern.
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The study confirmed that in Caucasian men with normal
sperm counts as well as in men with subnormal sperm counts
testosterone alone can produce azoospermia in about half
and suppression below 1 million in about two thirds of the
volunteers. The same proportion of men in both groups
appears to require an additional gestagen for full contracep-
tive protection. These results have a significant impact on the
eligibility of men for hormonal contraception as those with
subnormal semen parameters do not need to be treated sepa-
rately from those with normal parameters.
Synthetic androgens
19-nortestosterone
When searching for preparations with longer-lasting effec-
tiveness, 19-nortestosterone-hexoxyphenylpropionate was
tested. Its spectrum of effects is very similar to that of testos-
terone and it has been used as an anabolic steroid since the
1960s. The 19-nortestosterone ester injected every 3 weeks
enabled azoospermia to be reached by as many men as by
testosterone enanthate [19]. Thus, the 19-nortestosterone
ester is as effective as testosterone enanthate but allows
a longer interval between injections. However, as
19-nortestosterone is a synthetic androgen and testosterone
undecanoate has the advantage of a longer half-life and
being natural testosterone, 19-nortestosterone has not been
tested further.
7α-methyl-19-nortestosterone (MENT)
The synthetic androgen 7α-methyl-19-nortestosterone
(MENT) offers an approximately 10-fold higher potency to
suppress pituitary gonadotropins than testosterone. In con-
trast to testosterone, there is no 5α-reduction so that effects
on the prostate could be minimal. A first dose-finding study
showed that MENT administered in subcutaneous implants
was as effective as testosterone given alone in suppressing
spermatogenesis [20]. The potential of these implants either
alone or in combination with gestagen implants is currently
being investigated by the Population Council (New York).
Conclusion
Minimal serious adverse events were registered in the trials
with testosterone alone. In all studies, sperm counts returned
to normal levels, as a review of major studies also revealed,
so that one of the prime goals of male hormonal contracep-
tion, i.e., reversibility, is met [21]. In addition, a self-
applicable oral or/and transdermal application form would
be desirable as shown by the combination of transdermal
testosterone with oral gestagens [22,23]. However, long-
term studies extending over three or more years to ascertain
safety parameters especially in regard to the cardiovascular
system and to the prostate have not yet been performed. As
currently no pharmaceutical company is engaged in the
development of hormonal male contraception, clinical trials
sponsored by WHO and the Population Council or on a
smaller academic level will continue, but the “struggle for
hormonal male contraception” will continue for an undeter-
mined time period [24].
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